12:00 AM
 | 
Nov 01, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SPD 502 (NS1209): Began Phase I trial

Shire Pharmaceuticals Group plc (LSE:SHP; SHPGY), Andover, U.K.
Product: SPD 502 ( NS1209)
Business: Neurological
Therapeutic category: Receptor antagonist
Target:...

Read the full 91 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >